下一代肿瘤不可知靶点即将出现
Next-generation tumor-agnostic targets on the horizon.
肿瘤不可知药物开发将肿瘤学重新聚焦于共享的分子依赖性而非组织来源,从而能够针对跨肿瘤的罕见可操作驱动因素进行高效开发。
英文原题:SPP1+ macrophages in HR+ breast cancer are associated with tumor-infiltrating lymphocytes.
为探究 TIL 水平在不同亚型中的差异作用,我们对 31 例乳腺癌患者进行了单细胞 RNA 测序。
乳腺癌分为激素受体阳性(HR+)、HER2 阳性(HER2+)和三阴性(TNBC)等亚型,不同亚型的结局会随TIL(肿瘤浸润淋巴细胞)数量而异。为探究不同亚型中 TIL 水平所发挥的不同作用,我们对 31 例乳腺癌患者样本进行了单细胞 RNA 测序。TIL 水平高的 HR+ 乳腺癌显示 SPP1+ 巨噬细胞增多,其他单核细胞/巨噬细胞(mono/macro)亚群中的 SPP1 表达升高,并且这些亚群中与细胞外基质(ECM)重塑相关的通路富集。此外,细胞间相互作用分析显示,在 TIL 高水平 HR+ 乳腺癌中,SPP1+ 巨噬细胞与 T 细胞之间的 SPP1、MIF 和 FN1 信号增强。空间转录组数据进一步显示,在 TIL 高水平 HR+ 乳腺癌中,SPP1+ 巨噬细胞、CD8+ T 细胞与 CD4+ T 细胞彼此紧邻。我们的研究揭示了 SPP1+ 巨噬细胞对 TIL 高水平 HR+ 乳腺癌中 T 细胞的新型影响,可能有助于解释其不良预后,并为靶向干预提供线索。
Breast cancer categorized into hormone receptor-positive (HR+), HER2-positive (HER2+), and triple-negative (TNBC) subtypes, exhibits varied outcomes based on the number of tumor-infiltrating lymphocytes (TILs). To explore the divergent roles of TIL levels across different subtypes, we employed single-cell RNA sequencing on 31 patients with breast cancer. HR+ breast cancer with high TIL levels (TIL-high) revealed increased SPP1+ macrophages, increased SPP1 expression in other monocytes/macrophages (mono/macro) subgroups, and enriched pathways associated with extracellular matrix (ECM) remodeling in mono/macro. Moreover, cell-cell interaction analyses revealed enhanced SPP1, MIF, and FN1 signaling in the interaction between SPP1+ macrophages and T-cells in TIL-high HR+ breast cancer. Spatial transcriptomics data highlighted the close proximity of SPP1+ macrophages, CD8+ T-cells, and CD4+ T-cells in TIL-high HR+ breast cancer. Our findings unveil the novel influence of SPP1+ macrophages on T-cells in TIL-high HR+ breast cancer, potentially explaining the poor prognosis and offering insights for targeted interventions.
MEMBER ACCOUNT
登录成功会直接打开下一页。